VLA-4 mediated adhesion to bone marrow stromal cells confers chemoresistance to adherent lymphoma cells

C. D. Weekes, C. A. Kuszynski, John G Sharp

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

The mechanisms of maintenance of residual lymphoma in bone marrow during chemotherapy are currently not well understood. Previous studies have shown that primary lymphoma cells obtained from histologically negative bone marrow of non-Hodgkin's lymphoma (NHL) patients grew in long-term bone marrow cultures primarily in association with bone marrow stromal cells. Furthermore, the interaction of NHL patient cells with bone marrow stromal cells inhibited their spontaneous apoptosis. The current studies were designed to characterize the components of the heterotypic interaction between lymphoma cells and bone marrow stromal cells as well as to probe the consequences of this interaction as it pertains to the potential survival of minimal numbers of lymphoma cells during chemotherapy. Cellular adhesion assays performed in the presence of either neutralizing antibodies to VCAM- or the α and β subunit of VLA-4 resulted in >95%, 82% and 35% inhibition of lymphoma cell line adhesion to the bone marrow stromal line MS-5, respectively. Modulation of VLA-4 affinity by the 8A2 antibody resulted in enhanced secondary adhesion at 24 and 72 hours to either cellular fibronectin (65% and 65%) or MS-5 cells (60% and 55%), superceding levels obtained using untreated lymphoma cells (<20%). The bone marrow stromal cells induced a chemoprotective effect for adherent lymphoma cells over a 3-log dose range of vincristine, resulting in a 2-log increase in the ED50 at day 6 of culture. The failure of glutaraldehyde fixed stromal cells to induce a chemoprotective effect demonstrated that viable bone marrow stromal cells were necessary. Similarly, lymphoma/stromal cell conditioned medium also failed to provide a survival advantage. These data demonstrated that viable bone marrow stromal cells possessed the ability to actively inhibit the apoptotic pathways of intimately adherent lymphoma cells and this potentially contributes to their survival during chemotherapy.

Original languageEnglish (US)
Pages (from-to)631-645
Number of pages15
JournalLeukemia and Lymphoma
Volume40
Issue number5-6
DOIs
StatePublished - Jan 1 2001

Fingerprint

Integrin alpha4beta1
Mesenchymal Stromal Cells
Lymphoma
Bone Marrow
Stromal Cells
Drug Therapy
Non-Hodgkin's Lymphoma
Antibody Affinity
Survival
Glutaral
Vincristine
Conditioned Culture Medium
Neutralizing Antibodies
Fibronectins
Cell Adhesion
Cell Count
Maintenance
Apoptosis
Cell Line

Keywords

  • Adhesent lymphoma cells
  • Bone marrow stromal cells
  • Chemosesistance
  • VLA-4 mediated adhesion

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

VLA-4 mediated adhesion to bone marrow stromal cells confers chemoresistance to adherent lymphoma cells. / Weekes, C. D.; Kuszynski, C. A.; Sharp, John G.

In: Leukemia and Lymphoma, Vol. 40, No. 5-6, 01.01.2001, p. 631-645.

Research output: Contribution to journalArticle

@article{ddd6d6f0cdad46bd8d8c022e11ca8a3d,
title = "VLA-4 mediated adhesion to bone marrow stromal cells confers chemoresistance to adherent lymphoma cells",
abstract = "The mechanisms of maintenance of residual lymphoma in bone marrow during chemotherapy are currently not well understood. Previous studies have shown that primary lymphoma cells obtained from histologically negative bone marrow of non-Hodgkin's lymphoma (NHL) patients grew in long-term bone marrow cultures primarily in association with bone marrow stromal cells. Furthermore, the interaction of NHL patient cells with bone marrow stromal cells inhibited their spontaneous apoptosis. The current studies were designed to characterize the components of the heterotypic interaction between lymphoma cells and bone marrow stromal cells as well as to probe the consequences of this interaction as it pertains to the potential survival of minimal numbers of lymphoma cells during chemotherapy. Cellular adhesion assays performed in the presence of either neutralizing antibodies to VCAM- or the α and β subunit of VLA-4 resulted in >95{\%}, 82{\%} and 35{\%} inhibition of lymphoma cell line adhesion to the bone marrow stromal line MS-5, respectively. Modulation of VLA-4 affinity by the 8A2 antibody resulted in enhanced secondary adhesion at 24 and 72 hours to either cellular fibronectin (65{\%} and 65{\%}) or MS-5 cells (60{\%} and 55{\%}), superceding levels obtained using untreated lymphoma cells (<20{\%}). The bone marrow stromal cells induced a chemoprotective effect for adherent lymphoma cells over a 3-log dose range of vincristine, resulting in a 2-log increase in the ED50 at day 6 of culture. The failure of glutaraldehyde fixed stromal cells to induce a chemoprotective effect demonstrated that viable bone marrow stromal cells were necessary. Similarly, lymphoma/stromal cell conditioned medium also failed to provide a survival advantage. These data demonstrated that viable bone marrow stromal cells possessed the ability to actively inhibit the apoptotic pathways of intimately adherent lymphoma cells and this potentially contributes to their survival during chemotherapy.",
keywords = "Adhesent lymphoma cells, Bone marrow stromal cells, Chemosesistance, VLA-4 mediated adhesion",
author = "Weekes, {C. D.} and Kuszynski, {C. A.} and Sharp, {John G}",
year = "2001",
month = "1",
day = "1",
doi = "10.3109/10428190109097661",
language = "English (US)",
volume = "40",
pages = "631--645",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "5-6",

}

TY - JOUR

T1 - VLA-4 mediated adhesion to bone marrow stromal cells confers chemoresistance to adherent lymphoma cells

AU - Weekes, C. D.

AU - Kuszynski, C. A.

AU - Sharp, John G

PY - 2001/1/1

Y1 - 2001/1/1

N2 - The mechanisms of maintenance of residual lymphoma in bone marrow during chemotherapy are currently not well understood. Previous studies have shown that primary lymphoma cells obtained from histologically negative bone marrow of non-Hodgkin's lymphoma (NHL) patients grew in long-term bone marrow cultures primarily in association with bone marrow stromal cells. Furthermore, the interaction of NHL patient cells with bone marrow stromal cells inhibited their spontaneous apoptosis. The current studies were designed to characterize the components of the heterotypic interaction between lymphoma cells and bone marrow stromal cells as well as to probe the consequences of this interaction as it pertains to the potential survival of minimal numbers of lymphoma cells during chemotherapy. Cellular adhesion assays performed in the presence of either neutralizing antibodies to VCAM- or the α and β subunit of VLA-4 resulted in >95%, 82% and 35% inhibition of lymphoma cell line adhesion to the bone marrow stromal line MS-5, respectively. Modulation of VLA-4 affinity by the 8A2 antibody resulted in enhanced secondary adhesion at 24 and 72 hours to either cellular fibronectin (65% and 65%) or MS-5 cells (60% and 55%), superceding levels obtained using untreated lymphoma cells (<20%). The bone marrow stromal cells induced a chemoprotective effect for adherent lymphoma cells over a 3-log dose range of vincristine, resulting in a 2-log increase in the ED50 at day 6 of culture. The failure of glutaraldehyde fixed stromal cells to induce a chemoprotective effect demonstrated that viable bone marrow stromal cells were necessary. Similarly, lymphoma/stromal cell conditioned medium also failed to provide a survival advantage. These data demonstrated that viable bone marrow stromal cells possessed the ability to actively inhibit the apoptotic pathways of intimately adherent lymphoma cells and this potentially contributes to their survival during chemotherapy.

AB - The mechanisms of maintenance of residual lymphoma in bone marrow during chemotherapy are currently not well understood. Previous studies have shown that primary lymphoma cells obtained from histologically negative bone marrow of non-Hodgkin's lymphoma (NHL) patients grew in long-term bone marrow cultures primarily in association with bone marrow stromal cells. Furthermore, the interaction of NHL patient cells with bone marrow stromal cells inhibited their spontaneous apoptosis. The current studies were designed to characterize the components of the heterotypic interaction between lymphoma cells and bone marrow stromal cells as well as to probe the consequences of this interaction as it pertains to the potential survival of minimal numbers of lymphoma cells during chemotherapy. Cellular adhesion assays performed in the presence of either neutralizing antibodies to VCAM- or the α and β subunit of VLA-4 resulted in >95%, 82% and 35% inhibition of lymphoma cell line adhesion to the bone marrow stromal line MS-5, respectively. Modulation of VLA-4 affinity by the 8A2 antibody resulted in enhanced secondary adhesion at 24 and 72 hours to either cellular fibronectin (65% and 65%) or MS-5 cells (60% and 55%), superceding levels obtained using untreated lymphoma cells (<20%). The bone marrow stromal cells induced a chemoprotective effect for adherent lymphoma cells over a 3-log dose range of vincristine, resulting in a 2-log increase in the ED50 at day 6 of culture. The failure of glutaraldehyde fixed stromal cells to induce a chemoprotective effect demonstrated that viable bone marrow stromal cells were necessary. Similarly, lymphoma/stromal cell conditioned medium also failed to provide a survival advantage. These data demonstrated that viable bone marrow stromal cells possessed the ability to actively inhibit the apoptotic pathways of intimately adherent lymphoma cells and this potentially contributes to their survival during chemotherapy.

KW - Adhesent lymphoma cells

KW - Bone marrow stromal cells

KW - Chemosesistance

KW - VLA-4 mediated adhesion

UR - http://www.scopus.com/inward/record.url?scp=0035052462&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035052462&partnerID=8YFLogxK

U2 - 10.3109/10428190109097661

DO - 10.3109/10428190109097661

M3 - Article

C2 - 11426535

AN - SCOPUS:0035052462

VL - 40

SP - 631

EP - 645

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 5-6

ER -